2 Hedgehog proteins are lipid-modified secreted signaling molecules that regulate tissue development and homeostasis. Lipids contained in circulating lipoproteins repress the Hedgehog signaling pathway in the absence of Hedgehog ligand, but the identity of these lipids is unknown. Here, using biochemical fractionation and lipid mass spectrometry, we identify these inhibitory lipids as endocannabinoids. Endocannabinoids are present in lipoproteins of both flies and humans, and repress the pathway in both mammalian signaling assays and Drosophila wing imaginal discs. In Drosophila, endocannabinoids are required in vivo to keep the levels of Smoothened and full-length Cubitus interruptus (Ci 155 ) low in the absence of Hedgehog. Furthermore, elevating their endogenous levels inhibits Hedgehog-dependent accumulation of Smoothened and Ci 155 . Interestingly, cannabis-derived phytocannabinoids are also potent pathway inhibitors in flies and mammals. These findings constitute a novel link between organismal metabolism and local Hedgehog signaling, and suggest previously unsuspected mechanisms for the broad physiological activities of cannabinoids.
Introduction
The Hedgehog (Hh) pathway regulates growth, patterning and tissue homeostasis, and its ectopic activation underlies development of a variety of tumors [1, 2] . Covalent lipid modifications of Hh ligands are important for their signaling activity [3, 4] 
and allow both
Drosophila and mammalian Hh proteins to associate with lipoproteins [5] . These particles play multiple conserved roles in regulating Hh signaling. In addition to promoting the release of Hh and its mammalian homologue Sonic hedgehog (Shh), both Drosophila and mammalian lipoproteins also contain unknown lipids required to repress the pathway in the absence of lipoprotein-bound Hh ligands [5, 6] . The Hh receptor, Patched (Ptc), regulates lipoprotein trafficking in the Drosophila wing disc. When Hh is absent, Ptc lowers levels of the 7-pass transmembrane protein Smoothened (Smo) on the basolateral membrane, and blocks Smomediated accumulation of full-length transcriptional activator Cubitus interruptus (Ci 155 ), by a mechanism that requires lipoprotein lipids [6] . Lipoprotein-associated forms of Hh and Shh block pathway inhibition by lipoprotein-derived lipids [5, 6] . Both mammalian and Drosophila cells also secrete active, non-sterol-modified forms of Hh (HhN* and ShhN*) independently of lipoproteins. However, these forms cannot block pathway inhibition by lipoproteins [5] .
Identifying the endogenous lipoprotein lipids that repress Hh signaling is not only important for understanding the logic of the pathway, but could also suggest new types of pathway inhibitors for clinical applications. Therefore, we have used a combination of biochemical fractionation and lipid mass spectrometry to identify these molecules.
Results
Since initial experiments showed that very-low density lipoproteins (VLDL) carried lipids that were active in both Drosophila and ShhLIGHT2 cells [7] ( Figure S1A -B****), we used VLDL as a starting material for fractionation. We exploited both mammalian and Drosophila assays to assess pathway inhibition by lipid fractions derived from VLDL. First, we tested their ability to inhibit signaling by non-sterol modified ShhN* in mammalian ShhLIGHT2 cells.
Second, we asked whether these lipids could reverse the effects of lipoprotein knock-down in explanted Drosophila wing imaginal discs. We showed previously that knock-down of the Figure 1A and [6] ). Thus, these wing discs represent a powerful ex vivo assay for lipids that regulate Smo trafficking and activity.
To reduce the complexity of the VLDL lipid pool, we first subjected lipids to saponification and removed the resulting free fatty acids. Saponification depletes glycerolipids containing ester bonds (e.g. tri-, di-and monoacylglycerols, glycerophospholipids and sterol esters), but retains inhibitory activity of lipoprotein lipid extracts in mammalian ( Figure 1C and 1D) or Drosophila ( Figure 1A and 1B) assays. We fractionated saponified VLDL lipid extracts by reversed phase HPLC, assaying elution fractions for their ability to inhibit signaling by nonlipoprotein-associated Shh in ShhLIGHT2 cells. This revealed several clusters of elution fractions with inhibitory activity (red-shaded regions in Figure 2A ), and, surprisingly, one region with stimulatory activity (green-shaded region in Figure 2A ).
Since 7-dehydrocholesterol and its derivative Vitamin D3 inhibit mammalian Shh signaling (Figure S1D-F and [8] ), we first looked for these compounds using lipid mass spectrometry (MS/MS) and thin layer chromatography (TLC). MS/MS analysis did not detect Vitamin D3 at all. Furthermore, TLC analysis showed that repressive fractions did not coincide with the peak of sterols (not shown). Consistent with this, neither 7-dehydrocholesterol, nor any other sterol, reduced Smo levels in Drosophila Lpp RNAi wing discs, and Vitamin D3 had only weak effects (Figure S1G-I). Therefore, Vitamin D3 cannot be the conserved inhibitory lipid we seek.
Hydroxysterols have been shown to stimulate Smo activity [9, 10, 11] by binding to its Nterminal domain [11, 12, 13] . Although MS/MS analysis detected hydroxysterols in fractions [33] [34] [35] , no hydroxysterols were present in stimulatory elution fractions ( Figure S2A ). Thus, hydroxysterols do not account for the stimulatory activity detected in VLDL and are likely provided by other sources.
Since the active elution fractions did not correspond to peaks of previously reported pathway regulators, we used shotgun analyses by FTMS and MS/MS to search for other signaling lipids ( Figure S2G ). We detected a variety of sphingolipids, but these did not peak in active fractions ( Figure S2B -F) and were inactive in both ShhLIGHT2 and Drosophila wing imaginal disc cells (Figure S1J,K). However, MS/MS analysis revealed specific endocannabinoids that co-fractionated with each region of activity ( Figure 2 and Figure S2G ).
Endocannabinoids comprise an expanding family of endogenous compounds that consist of fatty acids and alcohols linked to various polar head groups. Arachidonoyl derivatives of ethanolamine, dopamine and glycerol are potent ligands for the G protein-coupled cannabinoid receptors CB 1 and CB 2 [14, 15, 16] . However, endocannabinoids with different fatty acid moieties and head groups also have interesting biological activities that do not appear to be exerted through cannabinoid receptors [17] . We identified peaks of N-acylethanolamides, Nacyldopamine and 2-alkylglycerols in elution fractions with repressive activity towards the Hh pathway; we also detected peaks of N-acylserines in fractions with stimulatory activity ( Figure   2 ). Thus, VLDL particles carry endocannabinoids that are candidates for Hh pathway inhibitors and activators.
To broadly assess the effects of endocannabinoids on Shh signaling, we assayed synthetically produced endocannabinoids in ShhLIGHT2 cells, including species from each endocannabinoid class found in stimulatory or inhibitory elution fractions. Members of each class potently modulated Hh signaling: N-acylserine 16:0, which we detected in the stimulatory elution fractions, stimulated signaling by ShhN* ( Figure 3A ). However, it did not activate signaling by itself (not shown). Interestingly, N-acylserine 20:4, which we did not detect in elution fractions, inhibited signaling ( Figure S3A Although these compounds were identified on the basis of their ability to inhibit signaling by ShhN*, they also potently inhibit signaling by lipoprotein-associated Shh ( Figure S3I and not shown). Taken together, these data indicate that specific endocannabinoids account for inhibitory activities found in VLDL, and that their effects mask the influence of additional, stimulatory endocannabinoids -the N-acylserines.
The activity of endocannabinoids on cannabinoid and vanilloid receptors is mimicked by the phytocannabinoids found in Cannabis. To examine whether Cannabis-derived cannabidiol, cannabinol or delta-9-tetrahydrocannabinol (THC) might also influence Hh signaling, we assayed their effects in ShhLIGHT2 cells. All three compounds potently repressed Shh pathway activity ( Figure S3J As expected, anandamide was present at nanomolar concentrations in human serum [18] , however other species containing different fatty acids were much more abundant; total concentrations of N-acylethanolamides, 2-acylglycerols, N-acylserines, 2-alkylglycerols were each in the micromolar range ( Figure S2H ). Interestingly, the concentration of each endocannabinoid class in the larval hemolymph was also in the micromolar range ( Figure S2I ). Thus, circulating endocannabinoids are present at levels sufficient to regulate the Hh pathway in vivo in both Drosophila and mammals.
The concentration at which a ligand is active will depend not only upon its affinity for its receptor, but also on other factors such as access to the receptor and ligand stability.
Endocannabinoids are rapidly taken up by cells and metabolized by intracellular enzymes, including fatty acid amide hydrolase (FAAH). This process can deplete even the extracellular pool of endocannabinoids [19, 20] . We wondered whether the Hh pathway might respond to lower concentrations of endocannabinoids if their rate of metabolism was reduced. To address this question, we assayed endocannabinoids in the presence of PF-3845, a selective FAAH inhibitor. PF-3845 potentiated the inhibitory activity of endocannabinoids such as N- Endocannabinoids bind to a variety of different receptors including CB1, CB2, TRPV, PPARα and a putative nonCB1/nonCB2 endothelial CB receptor [16, 17, 21, 22, 23, 24, 25, 26] . We wondered whether endocannabinoids might act through one of these different pathways to influence Smo. We therefore investigated the effects of specific synthetic agonists and antagonists of these receptors in the ShhLIGHT2 cell assay ( Figure S3S ). None of these compounds affected either basal or ShhN*-stimulated pathway activity. Thus, endocannabinoids do not act through these receptors to repress the Hedgehog pathway.
Discussion
Taken together, this work demonstrates that lipoprotein-derived endocannabinoids are Endocannabinoids require chaperones to move through the aqueous environment. There is evidence that serum albumin may carry these molecules [30] and our studies suggest that lipoproteins are also transporters for these lipids. Once present in the plasma membrane, these molecules are rapidly mobilized through the cytoplasm down a concentration gradient by various lipid transfer proteins [31] . This mobilization allows endocannabinoids to be degraded by a Competition between different endocannabinoids for these transport and degradation machineries has been shown to give rise to "entourage" effects in which addition of non-ligand molecules can indirectly increase the availability of the real ligand. We have observed that a broad range of different endocannabinoid classes and species influence Smo signaling. It may be that some of the molecules we have identified act indirectly via an entourage effect.
The finding that endocannabinoids in systemically circulating lipoproteins repress local Hh signaling demonstrates a fascinating link between systemic metabolism and Hh pathway activity in tissues. It suggests new mechanisms to coordinate organismal growth and development, and also has important implications for adult physiology. The fact that lipoprotein-derived endocannabinoids help to repress such an important tumor-promoting pathway suggests new possibilities to explain the link between disturbed lipoprotein metabolism and cancer risk [32] . In fact, cannabinoids block the growth of many tumors known to depend on Hh signaling [33, 34, 35, 36, 37, 38, 39, 40] .
Endocannabinoids and phytocannabinoids have a broad range of physiological activities that are not completely understood. Interestingly, Hh signaling regulates many of the same processese.g. angiogenesis [41, 42] , hair follicle development [43, 44] , nocioception [45, 46] , bone formation [47, 48] and energy metabolism [49, 50, 51] . Our findings forge a surprising link between cannabinoids and Hedgehog, opening new avenues of research for both important classes of signaling molecules.
Materials and Methods

Materials
Mammalian cells
ShhLIGHT2 cells [7] were maintained in DMEM + 10 % FBS, 150 µg/ml zeocin (Invitrogen) and 400 µg/ml G418 (Invitrogen). ShhLIGHT2 cells are NIH3T3 cells that express Firefly luciferase under the control of a Gli-responsive promoter, and Renilla Luciferase controlled by the viral Thymidine kinase promoter.
Mammalian expression plasmids
cDNA encoding human Shh in pCMV-XL5 vector was purchased from OriGene (SC300021).
Fly stocks
Oregon R flies, hs-flippase and adh-GAL4 are available from the Bloomington Stock Center. Transgenic line UAS<HcRed>dsLpp is described in [52] . Smoothened Agonist (SAG) was obtained from Santa Cruz Biotech.
Commercially obtained lipids
Induction of RNAi
LppRNAi was induced as described [52] .
Immunohistochemistry
Imaginal discs were fixed and stained as previously described [53] . Antibodies were diluted as follows: anti-Ci 2A1 1:10 [54], anti-Smo 1:50 [55] .
Image analysis
All quantified immunostaining was performed on discs that were dissected, fixed, stained and imaged in parallel using the same microscope settings. To quantify Ci 155 and Smo staining intensities, three apical sections 0.7 µm apart were projected using maximal intensity in Fiji. For each image, two rectangles of 100 pixels parallel to the A/P axis by 351 pixels parallel to the D/V axis were selected and centered at the AP boundary in ventral and dorsal compartments.
Average pixel intensity was determined as a function of distance from AP boundary using PlotProfile and plotted using Microsoft Excel. All AP boundaries were determined according to anti-Ci 155 coimmunostaining.
To estimate the significance of changes in staining intensities in discs of different genotypes, we measured Smo or Ci 155 staining intensity at the same distance from the AP boundary in each disc and calculated P values using Excel.
Lipoprotein isolation
VLDL, LDL and HDL were isolated from human serum (Sigma) according to [56] . Drosophila Lipophorin (Lpp) was isolated as described previously [6] .
Isolation of Drosophila larval hemolymph
Third instar larvae were washed in 10 % NaCl and disrupted using a loose dounce homogenizer in 1 % acetic acid in H 2 O with 50 µM PF-3845. The loose dounce allows release of the hemolymph but is not designed to disrupt the cells. The extract was centrifuged at 1000 g for 10 min. The supernatant containing hemolymph was centrifuged at 16000 g for 2 h to remove the debris; the supernatant was then subjected to lipid extraction.
Lipid extraction
Lipids from purified VLDL, LDL, HDL and Lpp particles applied as crude extracts in ShhLIGHT2 and wing disc signaling assays were extracted by a two-step Bligh and Dyer method [57] . Total lipid concentration was measured according to [58] . Lipoprotein-derived lipids were applied to LIGHT2 cells and wing discs at concentrations found in hemolymph/ human serum.
Preparation of saponification-resistant lipids
Dried VLDL lipid extracts were incubated at 80 ºC with 2 ml of 0.3 M methanolic potassium hydroxide for one hour. After cooling down to room temperature, the solution was extracted by two washes with diethyl ether. The ether fractions, which contain saponification-resistant lipids, were combined and subjected to further analysis.
Drosophila wing disc assay
The assay was performed as previously described [6] .
Wing discs dissected from either wild type or LppRNAi animals were incubated with DOPC liposomes (mock) or with liposomes consisting of DOPC:lipids to a ratio of 1:4, at indicated concentration. Non-saponifiable Lpp or VLDL, LDL and HDL lipids were added at concentrations corresponding to those present in the larval hemolymph or human plasma, respectively. After 2 hours at room temperature, discs were fixed and stained for Smo and/or Ci 155 according to the immunohistochemistry protocol and analyzed as described above. min. For signaling ShhLIGHT2 assay, lipoprotein-Shh was isolated by density centrifugation [59] and concentrated using Amicon Ultra -10K.
Preparation of Shh applied in the ShhLIGHT2 cell assay
ShhLIGHT2 signaling assay
ShhLIGHT2 cells are NIH3T3 cells that express Firefly luciferase under the control of a Gliresponsive promoter, and Renilla Luciferase controlled by the viral Thymidine kinase promoter.
The ratio of Firefly to Renilla Luciferase activity is a specific measure of Hh pathway activity. 24 h prior to assay, ShhLIGHT2 cells were plated at 10 5 / well in 96-well plates and then switched to a serum-free medium consisting of DMEM + 1 % ITS-X. In this medium, cells were then treated with nontransfected serum-free HeLa cell supernatants and DMSO or DOPC liposomes (mock) or with non-lipoprotein-associated Shh supplemented with DMSO or DOPC liposomes (Shh) or with different lipids or synthetic compounds.
Purified, commercially obtained lipids or synthetic compounds were added in DMSO at indicated concentration.
Elution fractions were added in DOPC liposomes in a ratio of 1:4.
Luciferase activity was assayed in cell lysates after 24 h, as instructed by the manufacturer (Dual Glo Luciferase Assay, Promega). The resulting Hh pathway activity was measured as the Firefly:Renilla ratio normalized to the ratio in cells that were not stimulated with Shh.
SAG competition assay
Smoothened Agonist (SAG) was added to the ShhLIGHT2 cells at indicated concentrations alone or in the presence of different endocannabinoids. Luciferase activity was assayed in cell lysates after 24 h, as instructed by the manufacturer (Dual Glo Luciferase Assay, Promega). The resulting Hh pathway activity was measured as the Firefly:Renilla ratio normalized to the ratio in cells that were not stimulated with Shh.
Column chromatography
Extracts containing saponification-resistant lipids from VLDL were loaded onto a C18 column 25mm x 4.5mm C18 column packed with 5 µM particles (Vydac, 218TP54). 500 µL of the extract was loaded in 60 % aqueous methanol and eluted with a step gradient of 80 % methanol in H 2 O (60 min) and a linear gradient of 80 % to 100 % methanol in water (40 min) at the flow rate of 1ml/min. The eluate was successively collected into 40 fractions that were dried down and subjected to the ShhLIGHT2 signaling assay.
Screening of endocannabinoid-containing fractions by direct infusion mass spectrometry
50 µl of each fraction was mixed with 65 µl of 13 mM ammonium acetate in iso-propanol. Prior to analyses, 20 µl of each sample were loaded into 96-well plate (Eppendorf, Hamburg), sealed with aluminum foil and centrifuged for 5 min at 4000 rpm on a Multifuge 3S-R centrifuge from Heraeus DJB Labcare Ltd (Newport Pagnell, UK). Mass spectrometric analyses were performed on a Q Exactive (Thermo Fisher Scientific, Bremen) instrument; samples were infused by a robotic nanoflow ion source TriVersa NanoMate (Advion BioSciences, Ithaca NY) controlled by the Chipsoft 6.4 software. We used nanoflow chips with a 4.1µm spraying nozzle diameter;
ionization voltage was +/-1.25 kV and gas back pressure was 0.95 psi. FTMS in positive and negative ion mode was acquired with target mass resolution of R m/z=200 =140000 within m/z range of 100-1000. Precursors within m/z range of 200-500 were fragmented in a data-dependent acquisition mode with the target resolution of R m/z=200 =17000.
Extraction of endocannabinoids from human blood serum and Drosophila larval hemolymph
All operations were performed at 4 °C in the cold room. To 500 µL of human serum or 500 µL (Tables S2 and S3 ).
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